Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuto Shimizu

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Endourology|October 16, 2025
Clinical Utility of Ureteral Optical Coherence Tomography for T Staging of Ureteral Cancer: NOCTURN StudyMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Japanese Journal of Clinical Oncology|December 9, 2022
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter studyMakito Miyake, Takuto Shimizu, Yuki Oda, et al.
International Journal of Clinical Oncology|August 27, 2022
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancerNobutaka Nishimura, Makito Miyake, Takuto Shimizu, et al.
European Heart Journal. Digital Health|March 20, 2024
Machine learning-based gait analysis to predict clinical frailty scale in elderly patients with heart failureYoshifumi Mizuguchi, Motoki Nakao, Toshiyuki Nagai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 19, 2019
Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective studyTakuya Owari, Makito Miyake, Yasushi Nakai, et al.
Journal of Bone Oncology|January 1, 2021
External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracyTakuya Owari, Makito Miyake, Yasushi Nakai, et al.
Methods and Protocols|August 28, 2024
A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE TrialMakito Miyake, Satoshi Anai, Yusuke Iemura, et al.
Cancer Management and Research|February 25, 2022
Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World DataMakito Miyake, Nobutaka Nishimura, Takuto Shimizu, et al.
Clinical Genitourinary Cancer|April 2, 2025
Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter StudyMakito Miyake, Nobutaka Nishimura, Yusuke Iemura, et al.
Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Endourology|October 16, 2025
Clinical Utility of Ureteral Optical Coherence Tomography for T Staging of Ureteral Cancer: NOCTURN StudyMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Japanese Journal of Clinical Oncology|December 9, 2022
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter studyMakito Miyake, Takuto Shimizu, Yuki Oda, et al.
International Journal of Clinical Oncology|August 27, 2022
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancerNobutaka Nishimura, Makito Miyake, Takuto Shimizu, et al.
European Heart Journal. Digital Health|March 20, 2024
Machine learning-based gait analysis to predict clinical frailty scale in elderly patients with heart failureYoshifumi Mizuguchi, Motoki Nakao, Toshiyuki Nagai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 19, 2019
Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective studyTakuya Owari, Makito Miyake, Yasushi Nakai, et al.
Journal of Bone Oncology|January 1, 2021
External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracyTakuya Owari, Makito Miyake, Yasushi Nakai, et al.
Methods and Protocols|August 28, 2024
A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE TrialMakito Miyake, Satoshi Anai, Yusuke Iemura, et al.
Cancer Management and Research|February 25, 2022
Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World DataMakito Miyake, Nobutaka Nishimura, Takuto Shimizu, et al.
Clinical Genitourinary Cancer|April 2, 2025
Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter StudyMakito Miyake, Nobutaka Nishimura, Yusuke Iemura, et al.
Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Pageof 8